02 · Monthly Pulse
Top signals across five segments, framed for consultant use. Evidence quality, trend velocity, and the so-what — updated monthly by Brendan Walsh.
Edition 05 · November 2026
November 2026The U.S. District Court for the District of Utah dismissed Xlear, Inc. v. FTC (No. 2:25-cv-00484-DBB-CMR, decided July 27, 2026) for lack of subject-matter jurisdiction, finding the dispute unripe. The court noted the FTC had already dropped its underlying enforcement case against Xlear in 2025, leaving no final agency action to challenge, and it did not reach the merits of whether the substantiation requirement exceeds the FTC's statutory authority.
Consumer search and social signals also inform velocity rating.
In June 2026 the FTC filed a motion seeking a contempt order against Amare Global and three individuals, alleging continued unsubstantiated depression, anxiety, and ADHD claims after an earlier settlement agreement.
Consumer search and social signals also inform velocity rating.
An 8-week trial of creatine hydrochloride and creatine ethyl ester reported measurable cognition and strength benefits in a perimenopausal and menopausal population, adding direct clinical data where the category previously leaned on general sports-nutrition research.
Consumer search and social signals also inform velocity rating.
Widely syndicated reporting in late 2025 laid out the serotonin-toxicity and G6PD-deficiency risks behind a drug most retailers sell without a supplement-registry listing. Biohacker demand, amplified by unconfirmed celebrity speculation, continues to outpace any resolution of its regulatory status.
Consumer search and social signals also inform velocity rating.
Multiple new ClinicalTrials.gov listings, covering gut-health biomarkers, exercise-induced inflammation, and broader GI and immune symptoms, show postbiotics moving from preclinical signal into active human trial activity.
Consumer search and social signals also inform velocity rating.